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Abstract
Background: Chloroquine is an anti-malarial drug being used to treat Plasmodium vivax malaria cases in Ethiopia.
However, emergence of chloroquine resistant strains of the parasite has challenged the current efficacy of the
drug. Therefore, the aim of this study was to assess the effectiveness of chloroquine against P. vivax strains in one
of the malaria endemic areas of Ethiopia, namely Halaba district, located in South Nations and Nationalities Peoples
Region (SNNPR) of South Ethiopia
Results: Among 87 malaria patients enrolled in the study, only 80 of them completed the 28-days follow-up.
Seven of them dropped from the study for different reasons. Among those study participants that completed their
follow-up, 69 were classified under the category of adequate clinical and parasitological response (ACPR). However,
the remaining 11 cases were considered as under treatment failure mainly due to recurrence of parasitemia on day
7 (four patients), day 14 (six patients), and day 21 (one patient). The age of all cases of treatment failures was
found to be less than 20 years. The load of parasitemia of patients with treatment failure on day of admission
(4709.4/μl) was higher than day of recurrence (372.37/μl). Parasite reduction ratio (PRR) of treatment failure cases
was 12.6/μl.
Conclusion: This report revealed the rise in treatment failure (13% [95% CI = 0.074 - 0.217]) as compared to earlier
reports from Ethiopia. It signals the spreading of chloroquine resistant P. vivax (CRPv) strains to malaria endemic
areas of Ethiopia. It is recommended that all concerned bodies should act aggressively before further expansion of
the current drug resistant malaria.
Introduction
The efficacies of anti-malarial drugs have been chal-
lenged by the emergence of drug resistant strains of
Plasmodium parasites. For more than 50 years, chloro-
q u i n e( C Q )w a st h ed r u go fc h o i c ef o re f f e c t i v et r e a t -
ment of uncomplicated malaria of all species [1].
Resistance to Plasmodium falciparium was first docu-
mented in 1986 from the border areas of Ethiopia [2]
several years after the firstr e p o r tf r o mS o u t h e a s tA s i a
and South America in the late 1950 s [3], followed by
gradual spread of the resistant strain throughout the
country [4-7]. The high level of CQ resistance of the
parasite necessitated change of choice from CQ to
sulphadoxine pyramethamine (SP) in 1998. Faster drop
in therapeutic efficacy of SP for the treatment of
uncomplicated falciparum malaria enforced the adoption
of Artemether-lumefanthrine (Coartem
®)( A L )i np l a c e
of SP as a first line treatment in 2004 [8,9].
Even though, significant numbers of clinical resistance
have been reported for a long time in most parts of
Asia, mainly from Indonesia [10-12], chloroquine resis-
tant strains of P. vivax was not known in Ethiopia until
recent years. It has been used as the first line drug for
many years for treatment of P. vivax infection. However,
after the first report from Debreziet, Ethiopia [13], gra-
dually a few reports are coming from some malaria
endemic areas of Ethiopia including Debrezeit (5%) [14],
Serbo, 3.6% [15], and Nazreth and Debrezeit (5.76%)
[16]. The present study was conducted in the southern
part of the country, in Halaba district. Unlike other
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etiological agents of malaria (P. falciparium and P.
vivax) in the study area are 30 and 70%, respectively
[17]. In addition, there was a report of antimalarial drug
resistant strain of P. falciparium f r o mt h es a m ed i s t r i c t
[9]. The high prevalence of P. vivax malaria and the pre-
sence of antimalarial drug resistant P. falciparium in the
study area could be an indicator for the possible emer-
gence of CRPv strains. In agreement with the hypoth-
esis, the outcome of the study showed the highest ever
reported decline in the efficacy of chloroquine drug
against P. vivax. Except for these few reports, however,
the nationwide prevalence of chloroquine resistant P.
vivax remains poorly studied. This necessitates country
wide survey for the current status of chloroquine resis-
tant P. vivax malaria in other malaria endemic areas of
the country.
Materials and methods
Study Site and Period
The clinical trial was conducted at Halaba Kulito Health
Center, located in Halaba town about 313 km south of
Addis Ababa, the capital city of Ethiopia (Figure 1). The
study site is situated withina na l t i t u d eo fr a n g i n gf r o m
1554 to 2149 m above sea level, longitude of 38° 7’ 0” E
and 7° 18’ 0” N latitude. The climatic zone of Halaba
district consists of mainly mid-land (’Weinadega’)a n d
low-land (’Kola’), which accounts for 86% and 14%,
respectively (as reported by the District Agriculture and
Rural Development Office). The annual rainfall is esti-
mated to be 857-1085 mm, while the mean annual tem-
perature varies from 17 to 20°C with a mean value of
18°C. The most common health problem in the district
is malaria [18]. Anopheles arabiensis is a chief vector of
the malaria parasite in the region [19]. The study was
conducted from January to February, 2009.
Study Subjects
Individuals seeking treatment for malaria infection at
Halaba Kulito Health Center during the study period
and having P. vivax mono-infection were enrolled in the
study. Based on the criteria set by WHO [20], 87
patients who fulfilled the inclusion criteria were
recruited for the study following their consent. Since
Figure 1 Map of the study site.
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area, the sample size was calculated by assuming a max-
imum of 5% treatment failures in the population, 5%
precision, 95% confidence interval, using the formula,
N=( Z / d )
2 P (1-P) [21] and 20% expected loss to
follow-up over 28 days.
Inclusion Criteria
The criteria used for inclusion of the study participants
were; age >6 months, positive for P. vivax mono-infec-
tion with parasite density above 250/μl, history of fever
during 48 hours prior to time of recruitment, ability and
willingness to participate in the study based on informa-
tion given to parent or guardian, access to health facility
and informed consent [20].
Exclusion Criteria
Presence of clinical conditions that requires hospitaliza-
tion, presence of severe malnutrition, pregnancy, signifi-
cant concomitant febrile illness which would interfere
with follow-up, chronic infectious diseases other than
malaria, known allergy and/or intolerance to drug (s)
being tested were the criteria used for exclusion of the
patients [20].
Patient Enrollment, Treatment and Follow-up
Patients confirmed to fulfill the inclusion criteria, and
volunteer to participate in the study were treated with
chloroquine under supervision of investigators and
health professionals working in the health center. Each
patient was treated with 25 mg base/kg of chloroquine
for three consecutive days [20] followed by seven fol-
low-up days (Day1, 2, 3, 7, 14, 21, and 28). For every
follow-up day and on any incident of malaria-like illness,
there was an examination of blood film (except on day
1), recording of temperature, and assessment of any
health problem and adverse drug reactions. During the
follow-up period, any patient who failed to come to the
health center on the scheduled date was traced to his/
h e rh o m ea s s i s t e db yt h el o c a lg u i d er e c r u i t e dd u r i n g
the study, and retained in the system unless it was
beyond the capacity to trace the lost patient for several
reasons (change of address, reluctance to continue as
the study subject, etc). In the in-vivo follow-up days,
patients who failed to respond to chloroquine of thera-
peutic dose were re-treated with quinine (10 mg base/
Kg), the second line drug in Ethiopia.
Laboratory analysis
Drug quality
The status of chloroquine phosphate (Batch number
1482, Adigrat Pharmaceutical Factory, Ethiopia), used to
treat all patients was checked for its quality before
administered to patients. Accordingly, five tests,
including weight variation, disintegration, dissolution,
identification and chloroquine hydrochloride injection
assay were made, following the standard procedures
recommended by British Pharmacopoeia, [22,23], using
standard facilities at Drug Administration and Control
Authority of Ethiopia (DACA). The drug was confirmed
to fulfill all international specifications set for the men-
tioned tests.
Parasite detection
Parasites were identified by microscopic observation of
the parasite’s morphology using duplicate thick and thin
blood smears taken on day of enrolment (Day 0). In
addition, blood slides were done at subsequent visits
(scheduled and non-scheduled). After fixing the thin
film in methanol, both the thin and thick smears were
stained with Giemsa (10%, pH~ 7.2) for 30 min and the
thick films were examined under oil immersion objec-
tive for malaria parasites. P. vivax asexual stages were
counted against 200 white blood cells (WBC), assuming
the median total WBC count of 8,000/μl.
Parasite density/µl=
Number of parasites × WBC count (8000)
Number WBC counted (200)
Parasite reduction ratio (PRR) on day of admission
and day 2 (after 48 hours) was evaluated as suggested by
W h i t e[ 2 4 ]u s i n gt h ef o r m u l aτ =P o/P2 (where Po is
parasite count on day 0 and P2 parasite count on day 2).
Quality Assurance
Each slide was carefully examined by experienced
laboratory technicians of Halaba Health Center. All P.
vivax positive and negative slides were re-examined by
senior laboratory technician at Jimma University.
Evaluation of Treatment Responses
The study population were classified into three cate-
gories; early treatment failure (in the case of persistence
of parasitemia up to day7), late treatment failure (in the
presence of parasite recurrence within 28 days follow-
up), and non-treatment failure (the absence of parasite-
mia in 28-days follow-up) [25].
Data Analysis
Data collected from in-vivo therapeutic efficacy test was
double entered and analyzed using SPSS software (ver-
s i o n1 6 . 0 ,C h i c a g o ,I L ,U S A ) .K a p l a n - M e i e rs u r v i v a l
probability analysis was used to evaluate treatment out-
come of the study participants during follow-up period.
Data of patient having mixed infection with P. falci-
parum and vomiting was excluded from the analysis.
While data of those patients lost to follow-up were
included in the analysis considering them as non-treat-
ment failure cases. In non-normally distributed data
(age), median was used to measure the central tendency.
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lyzed using geometric mean. In all analysis, significance
level was considered at 95% confidence interval.
Ethical clearance
The study protocol was reviewed and approved by Ethi-
cal Review Committee of Jimma University, College of
Natural Sciences. Written informed consent was
obtained from each patient or their guardians for patient
younger than 18 years.
Results
Enrollment and Baseline Characteristics
During the enrollment period from January 4 to 10,
2009 (six consecutive days), a total of 311 blood films of
patients suspected to have malaria infection were
inspected at Halaba Kulito Health Center. A total of 198
cases were positive for malaria infection and 119 cases
were confirmed to have P. vivax mono-infection. Only
87 of the 119, who fulfilled inclusion criteria set by
WHO [20], were included in the study and admitted to
the 28 days follow-up (Figure 2). The remaining 32
cases were not enrolled in the study mainly due to lack
of willingness, pregnancy, distance of their home from
the health center, history of using antimalarial drug
prior to seeking medication in the health center, and
chronic infection such as TB (Figure 2).
The socio-demographic and some clinical features of
the study subjects are as shown below (Table 1). Major-
ity of them were females (57.4%) and their median age
was 8 years (9 month - 52 years). The duration of their
illness (mean ± SD) before enrollment was 2.84 ± 2.5
days. About 61% had history of fever while 18% had
documented fever (axillary temperature ≥37.5°C) on the
day of admission. Their geometric mean parasite density
was 3072.77/μl.
Among 87 patients enrolled in the study, only 69 had
completed a 28-days follow-up. Seven of them were
excluded from the study at early stage of the follow-up
due to loss to follow-up (5 patients), vomiting (1
patient), and mixed infection with P. falciparium (1
patient) (Table 2). A total of eleven patients didn’tt o
respond to the therapeutic dose of chloroquine, and
they were categorized under treatment failure. As a
result, they were re-treated with quinine.
Treatment Response
Since CQ is a fast acting antimalarial drug, parasitaemia
clearance times for almost all patients involved in the 28
days in-vivo study were 48 hours except four patients
whose parasitaemia persisted for seven days. Relative
PRR of the study participants was 10.7/μl. Similarly,
gametocyte was detected for a week in 15 patients and
completely cleared on day 14. The study participants
were relatively not febrile on day of admission (36.7°C).
However, the body temperature dropped with follow-up
days. Likewise, patients with treatment failure on day of
recurrence were not febrile except three cases (age; 2, 4
a n d2 0 ) .V o m i t i n ga n dd i a r r h e a ,t h ec o m m o nm a l a r i a
symptoms were encountered in 11% and 19% of the
cases on day of admission, respectively, and disappeared
on day7.
Characteristics of Treatment Failures
In this study, about 13% (11/85) treatment failure was
observed (Table 2). Among the 11 treatment failures,
four were males and seven were females. In four of the
patients, parasitaemia persisted up to day 7, though the
load of parasitaemia was lower than the day of admis-
sion. From the early treatment failures, two of the cases
(a 20 years old female and a child aged 2 years) had
symptom of malaria on the day of recurrence. The other
nine treatment failures were observed on day 7 (two),
14 (six) and 21 (one) without showing symptom of
malaria. Parasite reduction ratio (PRR) of treatment fail-
ure cases was 12.6/μl (Table 3).
Discussion
Chloroquine has been in use both for treatment and
prophylaxis in health centers and the communities of
Ethiopia. It is an anti-malaria drug recommended by the
Ministry of Health of Ethiopia for treatment of P. vivax
malaria infection in the country. However, some reports
on chloroquine resistant P. vivax malaria (CRPv) are
coming from different malaria endemic areas of Ethiopia
[13-16]. In support of the earlier reports, our current
study also revealed significantly high treatment failure.
Furthermore, some of the other study participants (29%)
had complains of malaria symptoms such as headache,
fever, chilling, joint pain, and other symptoms during
the follow-up period although they were not confirmed
by recurrence of parasitemia in their blood. In agree-
ment with earlier reports from Indonesia, Peru, and
Ethiopia, most of the treatment failures recorded in this
study were children [14,26,27].
As stated by Baird [25], a subject that has an asexual
parasitemia of any level persisting to day 7 could be
classified as an early treatment failure. According to this
definition, four of the treatment failures documented in
this study were categorized under early treatment failure
and are definitively classified with a demonstration of
adequately absorbed, fully compliant therapy. On the
other hand, Baird [25] stated that an asexual parasitemia
that becomes undetectable but reappears at any time
between days 7 and 28 are classified as a recurrence
treatment failure. Similarly, seven of the treatment fail-
ures recorded in the study on day 14 (six) and 21 (one),
should be classified under this category (recurrence
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subjects having no recurrent parasitemia up to day 28
should be classified as having an infection that was sen-
sitive to chloroquine. Therefore, 69 of the study partici-
p a n t sw e r ep o s s i b l yi n f e c t e dw i t hc h l o r o q u i n es e n s i t i v e
strain of P. vivax
Treatment failure of P. vivax malaria after anti-malar-
ial drug treatment might not necessarily be an indica-
tion of the emergence of CRPv strains. There could be
other factors contributing to the failure such as malab-
sorpition of the drug, relapse, poor drug quality, re-
infection, low level of drug in blood, and recrudence of
parasitemia [28]. In this study, however, the possible
causes of the treatment failure were either malabsorp-
tion of the drug or recrudescence of parasitemia.
Because most of the treatment failures detected in this
s t u d yw e r ea tt h ee a r l ys t a g eo ft h ef o l l o w - u p( D a y7 ,
and 14, except one on day 21), on these days the blood
level of CQ and its metabolites do not drop to level
below minimum effective concentration. Thus, it can
prevent the recurrence of parasitemia of relapse or re-
infection up to 35 days [29].
Besides, for most of the early treatment failures (four),
the original parasite persisted up to day 7 though their
Figure 2 Flow chart of the study procedure.
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such a situation, it is impossible to think of the treat-
ment failures to be due to re-infection or relapse as a
new parasite needs a longer incubation period (ranges
from ten to seventeen days). In addition, Baird and
Hoffman [30] stated that in tropical areas like Ethiopia,
the challenge of a relapse could appear frequently but
does not commence before day17. In line with this
assumption, relapse could not be the cause for treat-
ment failure documented in this study as 91% of the
treatment failures were detected before day 17.
Treatment failures associated with drug resistance may
also be due to poor drug quality [31]. However, the
quality of drug used to treat all the patients was con-
firmed in the laboratory using international specifica-
tions set for each test. The drug used was confirmed to
have good quality and the treatment failures could not
be due to poor drug quality.
In-vivo therapeutic efficacy studies remain the ‘gold
standard’ method for assessing antimalarial drug effi-
cacy. However, due to the difficulty in classifying true
treatment failure, as recurrences of parasitemia (biologi-
cal resistant) or due to malabsorption of drug by
patients, supplementing it with other confirmatory tests
is important. For instance measurement of CQ and its
major metabolite DCQ in blood of patients with treat-
ment failures could clearly reveal the presence of malab-
sorption or recurrences of resistant parasites.
Conclusion
The treatment failure reported in this study (13%) was
relatively the highest as compared to earlier few reports
from Ethiopia and Africa. This report is a good indicator
of the emergence and spread of chloroquine resistant P.
vivax strains in malaria endemic area of Ethiopia. Thus,
besides taking the right measures by the concerned
bodies to control further expansion of resistance against
chloquine, more study on the degree of dissemination of
the resistance pattern within the P.vivax strains in other
malaria endemic regions of the country is recommended
to have clear picture of the country wide distribution of
the problem.
Abbreviations
ACPR: Adequate Clinical and Parasitological Response; CQ: Chloroquine;
CRPv: Chloroquine Resistant Plasmodium vivax; DACA: Drug Administration
and Control Authority of Ethiopia; PRR: Parasite Reduction Ratio; SNNPR:
Table 1 Characteristics of P. vivax malaria patients
enrolled in the in-vivo efficacy test of chloroquine in
Halaba Kulito Health Center, South Ethiopia, January
2009
Characteristics Day of admission
Median age in years (proportion) 8 years (9 month - 52 years)
< 5 years (40%) 3 years (9 month - 4 6/12 year)
5-14 years (15.3%) 7 years (5 year - 13 year)
15+ years (44.7%) 26 years (17 year - 52 year)
Sex
M 42.6% (36/87)
F 57.4% (51/87)
Mean Body Temp (°C). 36.7
History of fever 61% (n = 52)
Axillary Temp. ≥ 37.5°C 18% (n = 15)
Vomiting 11% (n = 9)
Diarrhea 19% (n = 16)
Geometric mean parasite 3072.77/μl
Day of illness (mean ± SD) 2.84 ± 2.5 days
Table 2 Response of study participants to chloroquine
drug during 28 days follow-up in Halaba Kulite Health
Center, South Ethiopia, January 2009.
Follow-
up
period
At
Risk
Excluded
from the
study
for
different
reasons
Treatment
failure
Survival
Probability
Estimate
0.95
Confidence
Interval
Lower
Limit
Upper
Limit
Day 0 87 0 0 1 0.9473 1
Day 1 87 4 0 1 0.9473 1
Day 2 84 0 0 1 0.9473 1
Day 3 83 2 0 1 0.9473 1
Day 7 81 0 4 0.9506 0.8755 0.9833
Day 14 72 0 6 0.8714 0.7784 0.9305
Day 21 60 1 1 0.8569 0.7617 0.9197
Day 28 58 0 0 0.8569 0.7616 0.9197
Table 3 Demographic, Parasitological and Clinical
features of patients with treatment failures in Halaba
Kulito Health Center, South Ethiopia, January 2009
Characteristics Proportion
Number of treatment failures 11
Male: Female 4:7
Median Age 7 years
Mean Weight 27.4 Kg
Mean body Temperature 37.6°C
Geometric mean parasite
On Day 0 4709.4/μl
On Day recurrence 372.37/μl
Parasite Reduction Ratio 12.6/μl
History of Fever 36.36 (n = 4)
Headache 27.2 (n = 3)
Vomiting 54.5 (n = 6)
Diarrhea 45.5 (n = 5)
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